Home > Insider Trading > Filing (0001437749-20-012379)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
834365	Biolife Solutions Inc	BLFS	Electromedical & Electrotherapeutic Apparatus (3845)	943076866

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1113655	Walter Villiger	Paradiesstrasse 25 Jona Switzerland Ch - 8645 V8 00000		No	No	Yes	No
1603260	Ag Holding Wavi	Paradiesstrasse 25 Jona Switzerland Ch - 8645 V8 00000		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-10-04	162,761	$15.36	3,315,586	No	4	S	Indirect	By WAVI Holdings AG
Common Stock	Acquisiton	2020-05-13	1,777,211	$4.75	5,092,797	No	4	X	Indirect	By WAVI Holdings AG
Common Stock	Disposition	2020-05-13	566,561	$14.90	4,526,236	No	4	S	Indirect	By WAVI Holdings AG
Common Stock	Acquisiton	2020-05-13	550,000	$1.75	5,076,236	No	4	X	Indirect	By WAVI Holdings AG
Common Stock	Disposition	2020-05-13	64,597	$14.90	5,011,639	No	4	S	Indirect	By WAVI Holdings AG

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By WAVI Holdings AG
No	4	X	Indirect	By WAVI Holdings AG
No	4	S	Indirect	By WAVI Holdings AG
No	4	X	Indirect	By WAVI Holdings AG
No	4	S	Indirect	By WAVI Holdings AG

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Warrants (Right to Buy)	Disposition	2020-05-13	1,777,211	$0.00	1,777,211	$4.75
Common Stock	Warrants (Right to Buy)	Disposition	2020-05-13	550,000	$0.00	550,000	$1.75

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2014-03-25	2021-03-25	No	4	X	Indirect
0	2016-05-12	2021-05-12	No	4	X	Indirect

Footnotes

On May 13, 2020, WAVI Holding AG ("WAVI"), an entity wholly owned by Walter Villiger (together, the "reporting person"), exercised an in-the-money warrant to purchase 1,777,211 shares of common stock, par value $0.001 per share (the "Common Stock"), of Biolife Solutions, Inc. (the "Company") with an exercise price of $4.75 per share pursuant to Rule 16b-6 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The reporting person exercised the warrant on a cashless basis pursuant to the terms of the warrant, resulting in the Company's withholding of 566,561 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 1,210,650 shares.
On May 13, 2020, the reporting person exercised an in-the-money warrant to purchase 550,000 shares of Common Stock of the Company with an exercise price of $1.75 per share pursuant to Rule 16b-6 under the Exchange Act. The reporting person exercised the warrant on a cashless basis pursuant to the terms of the warrant, resulting in the Company's withholding of 64,597 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 485,403 shares.
The warrants were issued to WAVI in March 2014 in connection with the conversion of outstanding promissory notes and interest accrued thereon for units consisting of common stock and warrants.
The warrants were issued to WAVI in May 2016 as partial consideration of a loan transaction.